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H eart failure, a debilitating disease accompanied by high morbidity and mortality, is prevalent globally. 1 Cardiac hypertrophy, characterized by enlarged heart size, enhanced protein synthesis, and re-expression of fetal genes is a critical and independent risk factor for ongoing heart failure. 2, 3 Originally, cardiac hypertrophy was considered an adaptive response to hypertrophic stimuli; however, prolonged overload eventually causes maladaptive hypertrophy. 4 During this progression, a variety of hypertrophic stimuli induce different proteases that participate in the degradation of both intracellular proteins for signal transduction and extracellular proteins involved in maintaining extracellular matrix homeostasis. 5, 6 Although numerous studies on the proteases have been conducted to uncover their complex interactions with the progression of pathological cardiac hypertrophy, the complex mechanisms remain elusive. 7 Among the various proteases, ADAMTS (A Disintegrin and Metalloproteinase With Thrombospondin Motifs), MMP (Matrix Metalloproteinase), and ADAM (a Disintegrin and Metalloproteinase) play critical roles in cardiovascular disease. [8] [9] [10] [11] [12] Belonging to the ADAMTS family, ADAMTS2 consists of a prodomain, a catalytic motif, a disintegrin-like module and an additional C-terminal sequence. 13, 14 The primary function of ADAMTS2 is to promote cleavage of the amino propeptides of types I, II, III and V procollagens, and a lack of ADAMTS2 causes dermatosparaxis in humans (Ehlers-Danlos syndrome type VIIC). 15 ADAMTS2 is expressed in various adult tissues, including the heart tissues, and is also involved in multiple biological processes. [15] [16] [17] [18] [19] [20] Recently, an investigation reported that elevated expression of ADAMTS2 was observed in samples of culprit coronary lesions obtained from patients with acute myocardial infarction. This study indicated a potential role of ADAMTS2 in the pathogenesis of acute myocardial infarction and cardiovascular disease. 21 However, the exact role of ADAMTS2 in cardiovascular disease is still unclear.
Herein, we observed a striking elevation in ADAMTS2 expression in human dilated cardiomyopathic hearts, a pressure overload-induced mouse cardiac hypertrophy model and angiotensin II (Ang II)-induced cardiomyocyte hypertrophy. Further testing of the regulatory effect of ADAMTS2 in transgenic mice models showed that the extent of cardiac hypertrophy was exaggerated in ADAMTS2 knockout (ADAMTS2-KO) mice and relatively 
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Materials and Methods
All the procedures involving human samples abided by the principles outlined in the Declaration of Helsinki and were approved by the Ethics Committee at Nanjing Medical University. 
Statistical Analysis
Data are presented as the mean±SD. All statistical analyses were assessed with SPSS software, version 19.0. An unpaired Student t test was performed for comparisons between 2 groups. Comparisons among >2 groups were conducted by 1-way ANOVA followed by Bonferroni post hoc test (assuming equal variances) or Tamhane T2 test (without the assumption of equal variances). A value of P <0.05 was considered as statistically significant.
Results
ADAMTS2 Is Upregulated During Cardiac Hypertrophy
We tested the protein expression of ADAMTS2 in human heart samples from patients with dilated cardiomyopathy and from normal donors. Western blotting results suggested that ADAMTS2 expression was predominantly elevated in failing human hearts ( Figure 1A ), as was expression of the hypertrophic markers atrial natriuretic peptide (ANP) and β-myosin heavy chain (β-MHC). In accordance with the data above, in a murine model of aortic banding (AB)-induced cardiac hypertrophy, 4-week AB-treated mice exhibited dramatically increased ADAMTS2 protein expression ( Figure 1B) . Likewise, markedly elevated expression of ANP and β-MHC was consistent with the alteration of ADAMTS2. In addition, 8-week AB-treated mice exhibited a significantly higher extent of expression. Furthermore, NRCMs were treated with Ang II (1 μmol/L) for 24 or 48 hours to induce cardiomyocyte hypertrophy in vitro. As expected, ADAMTS2, ANP, and β-MHC protein expression was significantly increased after 24 hours of Ang II administration and remained higher after 48 hours compared with that of the control group treated with phosphate-buffered saline ( Figure 1C ). These data raised the possibility that ADAMTS2 may be involved in cardiac hypertrophy and heart failure.
Loss of ADAMTS2 Aggravates Pressure OverloadInduced Hypertrophy
To explore the exact effect of ADAMTS2 during cardiac hypertrophy in vivo, we used a global ADAMTS2-KO mouse model to confirm the absence of ADAMTS2 expression via Western blotting ( Figure S1 in the online-only Data Supplement). At baseline, ADAMTS2-KO mice appeared normal in terms of morphometric and contractile functions (Table  S2) . However, after 4 weeks of AB treatment, ADAMTS2-KO mice showed markedly exacerbated cardiac hypertrophy, as evidenced by increased heart weight (HW)/body weight (BW), lung weight/BW, and HW/tibia length ratios compared with those in wild-type (WT) mice 4 weeks after AB surgery ( Figure 2A ). Moreover, a notable increase was observed in the cardiomyocyte cross-sectional areas in left ventricular tissue from WT mice, as indicated by wheat germ agglutinin staining, although this change was dramatically aggravated in the ADAMTS2-KO mice ( Figure 2B and 2C). Furthermore, the ADAMTS2-KO mice with AB treatment showed remarkably increased cardiac dilation and deteriorative cardiac dysfunction according to echocardiographic assessments (ie, left ventricular end-systolic dimension, left ventricular end-diastolic dimension, and fractional shortening) compared with WT mice ( Figure 2E ). Fibrosis was also assessed to study the alterations in maladaptive cardiac hypertrophy with ADAMTS2 deficiency. Paraffin-embedded heart tissue sections were stained with picrosirius red to calculate the extent of cardiac fibrosis. Remarkable interstitial and perivascular fibroses were observed in the AB-treated WT mice, and the extent of fibrosis was more prominently evident in ADAMTS2-KO mice subjected to AB surgery ( Figure 2B and 2D) . Consistent with the above findings, the mRNA expression of hypertrophic markers, such as ANP, brain natriuretic peptide, and β-MHC, and fibrotic markers, including connective tissue growth factor, collagen I, collagen III, fibronectin, MMP-2, and MMP-9, was significantly higher in ADAMTS2-KO mice than in WT mice ( Figure 2F ). Collectively, these data suggested that the loss of ADAMTS2 exacerbated pressure overload-induced cardiac hypertrophy.
Overexpression of ADAMTS2 in the Heart
Attenuates Pressure Overload-Induced Cardiac Hypertrophy TG mice with cardiac-specific overexpression of ADAMTS2 were generated using Cre-LoxP techniques as described in the schematic diagram ( Figure S2A ). Four independent lines of ADAMTS2 transgenic mice (TG1, TG2, TG3, and TG4) were established, and Western blotting assays were conducted to confirm transgene expression ( Figure S2B ). Under normal conditions, none of the generated ADAMTS2 TG mice manifested any alteration in cardiac morphology or contractile function when compared with their CAG-CAT-ADAMTS2/MHC-Cre (CAMC) littermates without tamoxifen administration (Table S3) . Finally, we chose the offspring of TG4 mice that expressed the highest ADAMTS2 levels for the subsequent experiments. After 4-week AB treatment or sham operation, the hypertrophic response was observed to be blunted in ADAMTS2-TG mice, as was verified by the lower HW/BW, lung weight/BW, and HW/ tibia length ratios in TG mice when compared with CAMC mice ( Figure S3A ). Similarly, a significantly decreased cardiomyocyte cross-sectional area was noted in AB-treated ADAMTS2-TG mice compared with the control group ( Figure 3A and 3B). Furthermore, TG mice displayed profoundly improved cardiac structure and function compared with CAMC littermates undergoing AB treatment with echocardiographic measurements ( Figure S3B ). Subsequently, a cardiac fibrosis study was conducted by calculating the collagen volume in the interstitial and perivascular spaces. Picrosirius red staining showed that ADMTS2-TG mice had prominently alleviated cardiac fibrosis when compared with CAMC mice (Figure 3A and 3C). Consistent with these findings, the mRNA expressions of ANP, brain natriuretic peptide, β-MHC, connective tissue growth factor, collagen I, collagen III, fibronectin, MMP-2, and MMP-9 were dramatically decreased in TG mice subjected to AB compared with CAMC mice ( Figure S3C ). In summary, the gain-of-function study demonstrated that cardiac-specific overexpression of ADAMTS2 attenuates pressure overload-induced cardiac hypertrophy.
ADAMTS2 Modulates Ang II-Induced NRCM Hypertrophy In Vitro
To determine whether ADAMTS2 contributes to cardiac myocyte hypertrophy, gain-and loss-of-function studies in NRCMs were performed in vitro. NRCMs were isolated and infected with AdshADAMTS2 or AdADAMTS2 to knockdown or overexpress ADAMTS2, respectively ( Figure S4A ). Subsequently, NRCMs were administered either Ang II (1 μmol/L) or phosphate-buffered saline as a control for 48 hours, followed by immunostaining with α-actinin to assess cardiomyocyte cross-sectional areas and RT-PCR to measure the expression of hypertrophic markers. No obvious difference was observed in cell size among AdshADAMTS2, AdADAMTS2, and their respective phosphate-buffered saline-treated control groups at baseline ( Figure S4B ). However, ADAMTS2 knockdown notably enhanced Ang II-induced cardiomyocyte hypertrophy according to the assessment of cell surfaces ( Figure S4B and S4C) . In addition, the overexpression of ADAMTS2 in NRCMs resulted in markedly decreased cell sizes compared with those of cells in the control group ( Figure S4B and S4D ). In parallel with the above findings, the mRNA expressions of ANP, brain natriuretic peptide, and β-MHC were significantly upregulated in AdshADAMTS2-infected NRCMs ( Figure S4E ) but markedly downregulated in AdADAMTS2-infected NRCMs ( Figure S4F ) after treatment with Ang II compared with the controls. Moreover, our functional experiment in vitro partly confirmed that exogenous recombinant ADAMTS2 with different concentrations could mitigate cardiac myocytes hypertrophy ( Figure S5 ). Together with the in vivo experiments, these results support the conclusion that ADAMTS2 functions as a negative regulator of cardiac hypertrophy.
ADAMTS2 Decreases AKT Phosphorylation On Hypertrophic Stress
In an attempt to elucidate the signaling mechanisms by which ADAMTS2 exerts a protective role in cardiac hypertrophy, Western blotting assays were performed, and the results demonstrated that AB-induced AKT activation was significantly increased in ADAMTS2-KO mouse hearts and that AKT phosphorylation levels were markedly attenuated in AB-treated ADAMTS2-TG mice compared with each respective control ( Figure 4A and 4B) . Similar alterations in molecules downstream of AKT (GSK3β [glycogen synthase kinase-3 β], mTOR (Mammalian Target of Rapamycin), and P70S6K) were also observed. To further explore the connection between ADAMTS2 and the AKT pathway, we tested PI3K, a molecule upstream of AKT, and observed that phosphorylation of the PI3K p85 subunit was greatly increased in ADAMTS2-KO mouse hearts but markedly downregulated in ADAMTS2-TG mouse hearts ( Figure 4A and 4B) . Surprisingly, the expression of phosphorylated FAK, a candidate for the activation of PI3K, increased in ADAMTS2-KO mouse hearts compared with mice in the control group ( Figure 4A) . Likewise, decreased phosphorylated FAK expression was identified in the heart of ADAMTS2-TG mice compared with their control littermates ( Figure 4B ). Consistent with these data in vivo, ADAMTS2 knockdown increased phosphorylation levels of the PI3K/AKT-dependent signaling pathway in Ang II-treated NRCMs, whereas ADAMTS2 overexpression alleviated these changes ( Figure S6A and S6B) . Given these findings, we concluded that the protective role of ADAMTS2 in pathological cardiac hypertrophy is mediated by the inhibition of AKT-dependent signaling.
Inactivation of PI3K/AKT-Dependent Signaling Pathways Blunts the Deteriorative Effect of Cardiac Hypertrophy Induced by Deficiency of ADAMTS2
With the aim of verifying the hypothesis that ADAMTS2 exerts its protective role in pathological cardiac hypertrophy via regulation of the PI3K/AKT-dependent signaling pathway, the PI3K-specific inhibitor LY294002 was administered to ADAMTS2-KO mice before the AB operation. The results of Western blotting assays suggested that LY294002 completely blocked phosphorylation of the PI3K/ AKT-dependent signaling pathway in AB-treated mouse hearts ( Figure 5A) . Strikingly, the ratios of HW/BW, lung weight/BW, and HW/tibia length were decreased ( Figure  S7A ) in LY294002-treated mice compared with DMSO (dimethyl sulfoxide)-treated mice. Along with these findings, a marked decline in the cross-sectional areas of cardiomyocytes ( Figure 5B and 5C) was also observed. Further echocardiographic measurements revealed the amelioration of hypertrophic phenotypes with preserved contractile function in ADAMTS2-KO mice after the injection of LY294002 ( Figure S7B ). Moreover, LY294002-treated mice rescued cardiac fibrosis in response to hypertrophic stimuli ( Figure 5B and 5D ). On Ang II stimulation, we performed an in vitro study with a specific AKT inhibitor AKTI IV in AdshADAMTS2-infected NRCMs. As shown in Figure S8 , AKTI IV significantly mitigated the hypertrophic growth of AdshADAMTS2-infected NRCMs induced by 60 minutes Ang II treatment and decreased phosphorylation levels of the PI3K/AKT-dependent signaling pathway. In summary, the protective effect of ADAMTS2 on pathological cardiac hypertrophy could be mediated by inactivation of the PI3K/ AKT-dependent signaling pathway.
Discussion
To our knowledge, the primary function of ADAMTS2 is the cleavage of amino propeptides of types I, II, III, and V procollagens, and it plays an important role in fibrosis. 25 Previous study demonstrated that ADAMTS2 mutations in mice resulted in symptoms, such as fragile skin and male sterility. 15, 26 However, we found no cardiac phenotype of ADAMTS2-KO mice in terms of morphometric and functional parameters at baseline. After subjected to AB, however, fibrosis was more evident in ADAMTS2-KO mice but attenuated in ADAMTS2-TG mice. Here, we first suggest that a protective function of ADAMTS2 in the development of cardiac hypertrophy under pathological conditions is independent of its primary function, but additional studies should be conducted to confirm these findings.
The ADAMTS family, which includes 19 secreted enzymes, has been reported to be involved in various human biological processes. 27 A previous investigation suggested that ADAMTS2 functions as a tumor suppressor in HUVECs (human umbilical vein endothelial cells). 19 Moreover, several previous studies suggested that tumor suppressors could negatively modulate cardiac hypertrophy. 22, 28 Interestingly, we found that ADAMTS2 expression was upregulated in failing human hearts, AB-induced hypertrophic mouse hearts, and NRCMs treated with Ang II. On the basis of these findings, it is possible that ADAMTS2 may function as an important regulator of cardiac hypertrophy. Our experimental results confirmed that ADAMTS2 indeed plays a protective role in cardiac hypertrophy. In addition, ADAMTS1 was suggested to serve as a mediator of the induction of alterations in collagen and elastin in myocytes in response to ethanol. 29 Moreover, suppressed myocardial expression of ADAMTS4 improves cardiac function in rats with pressure overload-induced hypertrophy. 30 Considering the similarities in molecular construction and function between ADAMTS1/4 and ADAMTS2, these results firmly suggest that ADAMTS2 may serve as a promising target for preventing cardiac hypertrophy and heart failure.
The PI3K/AKT signaling pathway is a key contributor to the process of cardiac hypertrophy. 31, 32 Several researchers assumed that pathological hypertrophic stress and prolonged activation of PI3K/AKT could cause pathological cardiac hypertrophy. 33, 34 On hypertrophic stimulation, PI3K is activated, leading to AKT activation. AKT facilitates cardiac hypertrophy through its negative effects on GSK3β and its positive effects on mTOR, which promotes the phosphorylation of p70S6 kinase and the synthesis of proteins. 35 Recently, Du et al 36 suggested that ADAMTS9 is a critical tumor suppressor in gastric cancer progression through the inhibition of oncogenic AKT/mTOR signaling. Sharing a homologous structure with ADAMTS9, ADAMTS2 may exert its antihypertrophic function through the repression of PI3K/AKT signaling. Notably, in our study, phosphorylation of the PI3K/AKT-dependent pathway was significantly enhanced in ADAMTS2-KO mice with AB treatment, whereas the phosphorylation extent was dramatically suppressed by the overexpression of ADAMTS2. Furthermore, LY294002 and AKTI IV successfully blunted the hypertrophic response both in vivo and in vitro, which confirmed our conclusions. However, our findings are inconsistent with a previous investigation which showed that ADAMTS2 could exert its antiangiogenic and antitumoral effects on HUVECs via the downregulation of extracellular signal-regulated kinase phosphorylation. We speculated that the mechanism of ADAMTS2 may be tissue/cell/circumstance dependent.
To access factors upstream of AKT signaling, in our experiment, an elevated phosphorylated FAK expression in ADAMTS2-KO mice subjected to AB for 4 weeks was observed, although overexpression of ADAMTS2 altered this change. Because FAK could directly bind to the PI3K subunit p85 and induce the phosphorylation of PI3K, 37 we also found increased expression of activated PI3K in ADAMTS2-deficient mice undergoing AB treatment. In addition, ADAMTS2-TG mice showed downregulated expression of phosphorylated PI3K. Previous investigations showed that FAK plays an important role in cardiac hypertrophy. 38, 39 Recently, Zhu et al 23 claimed that FAK activation could aggravate AB-induced cardiac hypertrophy. Because FAK is well known as a vital mediator in both embryonic and adult heart, 40 it is conceivable that ADAMTS2-induced antihypertrophic effects could rely on inactivation of the PI3K/AKT-dependent signaling pathway. As an extracellularly secreted protein, ADAMTS2 has unique advantages as a therapeutic target because of the convenience of exogenous intervention, the accessibility of regulation via multiple post-transcriptional modifications and the lower side effects under normal conditions. Our subsequent in vitro functional experiment with recombinant ADAMTS2 in NRCM at different concentrations has proved that exogenous recombinant ADAMTS2 could mitigate cardiac myocyte hypertrophy by lowing cell surface areas, relative mRNA levels of ANP, and phosphorylated PI3K and AKT protein levels. However, a limitation of our study is that we failed to provide direct evidence to describe how ADAMTS2 modulates cardiac myocytes in a protective role, and further studies need to be conducted.
In summary, we propose that ADAMTS2 regulates the hypertrophic response through inhibiting the activation of the PI3K/AKT-dependent signaling pathway. Because ADAMTS2 is an extracellular protein, it could be effectively manipulated using pharmacological means to modulate cardiac hypertrophy. Here, we conclude that ADAMTS2 may represent a novel therapeutic target for treating pathological cardiac hypertrophy.
Perspectives
This investigation is the first to delineate the protective function of ADAMTS2 in pathological cardiac hypertrophy. As a metalloproteinase, in addition to its primary function, ADAMTS2 can suppress the PI3K/AKT-dependent signaling pathway through the dephosphorylation of FAK. Our findings highlight the critical role of ADAMTS2 in inhibition of the PI3K/AKT-dependent signaling pathway in the process of cardiac hypertrophy and indicate that ADAMTS2 may serve as a novel therapeutic target for the treatment of cardiac hypertrophy and heart failure.
